BusinessCapricor Announces Initiation of HOPE-2 Clinical Trial of CAP-1002 for Duchenne Muscular DystrophyBy Nasdaq OMXApr 30, 2018, 11:01 AM UTC
BusinessCapricor Presents Fourth Quarter and Full Year 2017 Financial Results and Corporate UpdateBy Nasdaq OMXMar 14, 2018, 8:00 PM UTC
BusinessNew Published Study Reports Cardiosphere-Derived Cells Improved Skeletal and Cardiac Muscle Function in Mouse Model of Duchenne Muscular DystrophyBy Nasdaq OMXFeb 22, 2018, 6:22 PM UTC
